Jeremy Renner's peptide stack (via @PeptideList): Thymosin, BPC-157, MOTS-c, TB-500, NAD, hormones
Jeremy Renner casually listing peptides tells you where this market is going. Thymosin. BPC-157. MOTS-c. TB-500. NAD. Hormones. The celebrity stack gets attention. The biology decides whether it makes sense. Same peptide. Different body.
@PeptideList nails the framing — celebrity stack gets attention, biology decides if it makes sense — and on biology, this is more inventory than protocol. TRT + BPC-157 + TB-500 has a defensible logic for an older actor recovering from a serious injury, and MOTS-c is the one underrated entry in the list. But 'Hormones' and 'NAD' carry zero information without specifics, and 'Thymosin' (alpha-1?) at unstated dose is mostly a vibe. The compounds have legitimate places — the listing doesn't show that any of them are being used legitimately.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 79 | C+ | 25% | Thymosin Alpha-1 (immune-aging), MOTS-c, NAD precursors, and TRT all have legitimate longevity-relevant mechanisms; the stack reads as a defensible aging-male protocol when read charitably. |
| Cognition | — | Not targeted | — | No ingredient in the listed stack has a primary cognitive mechanism; any benefit would be downstream of TRT mood/fatigue effects, which are too uncertain given 'Hormones' is unspecified. |
| Sleep & recovery | 74 | C | 20% | BPC-157 + TB-500 is a coherent recovery-peptide pair commonly used for soft-tissue rehabilitation. Without doses, evidence remains anecdotal. |
| Energy & metabolism | 77 | C+ | 30% | MOTS-c has a real mitochondrial-AMPK mechanism with some human data. NAD precursors have weaker but legitimate metabolic mechanism. TRT supports daily energy in hypogonadal men. |
| Body recomposition | 76 | C | 25% | If 'Hormones' includes TRT, body-comp benefit in older men is well-evidenced. The lack of disclosure is what holds this off the B range. |
Ingredients (6)
Thymosin Alpha-1
Thymosin Alpha-1 on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- Synthetic version of a thymic-derived 28-amino-acid peptide; immunomodulator with FDA-orphan-drug status for some indications and EU approval for chronic hepatitis B. Modulates T-cell maturation and innate immune function.
- Take
- If 'Thymosin' here means Thymosin Alpha-1 — the immune-modulating thymic peptide, distinct from TB-500 which is a Thymosin Beta-4 fragment also listed in this stack — it's the most evidence-backed ingredient in the list. Subcutaneous use at 1.6mg twice weekly is the published HBV protocol; longevity and general-immune protocols vary widely. Without specifying which thymosin or what dose, this is just a brand name.
BPC-157
- Dose
- unspecified
- Mechanism
- Pentadecapeptide derived from a gastric protein; preclinical evidence for angiogenesis, fibroblast migration, and growth factor signaling. No published human RCTs.
- Take
- Common in recovery-focused stacks. No dose disclosed in the source; typical research-peptide protocols use 200–500mcg/day subQ. For an older actor with an extensive injury history, the rationale is more defensible than for a healthy 25-year-old — but 'rationale' isn't 'evidence.'
MOTS-c
- Dose
- unspecified
- Mechanism
- Mitochondrial-derived 16-amino-acid peptide encoded by mitochondrial DNA; AMPK activator with metabolic effects on insulin sensitivity, glucose homeostasis, and exercise capacity in animal and small human studies.
- Take
- MOTS-c is the most mechanistically interesting entry in the listing — actually-novel biology, not a re-skinned recovery peptide. Research-vendor protocols use 5–10mg/week subQ. Human data is limited but suggestive on metabolic markers and exercise capacity. Without dose or duration, can't evaluate further, but it's the one ingredient where 'celebrity attention' might actually point at something underexplored.
TB-500
- Dose
- unspecified
- Mechanism
- Synthetic fragment of thymosin beta-4; preclinical evidence for actin-binding effects on cell motility and tissue repair. No human trials in this indication.
- Take
- Routinely paired with BPC-157 in recovery stacks. Research-vendor 'loading-phase' protocols use 2–5mg/week. As with BPC-157, the case for use in a serious-injury context is more defensible than the case for use in healthy individuals — but the source doesn't tell us either way.
NAD
- Dose
- unspecified
- Mechanism
- NAD+ is a coenzyme central to mitochondrial energy production and sirtuin/PARP enzyme activity; declines with age. Supplemented as IV NAD+, oral NMN/NR precursors, or subcutaneous NAD+.
- Take
- 'NAD' as listed could be IV NAD+ (typical $300–1500/session with essentially no published evidence of clinical benefit), or oral NMN/NR precursors at 500–1000mg/day with weak biomarker evidence. The two have wildly different cost-effectiveness profiles and are not interchangeable. The vagueness is doing a lot of work here.
Hormones (unspecified)
- Dose
- unspecified
- Mechanism
- An umbrella covering TRT, GH/IGF-1, thyroid (T3/T4), DHEA, and others. Each has distinct mechanisms, evidence bases, dose ranges, and risk profiles.
- Take
- 'Hormones' carries zero information. TRT for hypogonadal men has decades of evidence and a clear dose range; GH or IGF-1 stacks have a much less favorable risk profile and require active monitoring; thyroid (T3/T4) is its own thing entirely. A celebrity 'hormones' listing is most likely TRT, but the lack of disclosure forecloses real evaluation and the difference between 'TRT 100mg/wk' and 'GH 4 IU/day' is not cosmetic.
Risks & interactions
- 'Hormones' is an undefined umbrella with very different risk profileshigh
TRT for hypogonadal men has a well-characterized risk profile (hematocrit, E2, PSA monitoring at standard cadence). GH/IGF-1 carries cancer-progression and cardiac concerns at supraphysiologic doses. Thyroid suppression is a different category again. A reader who mimics 'Hormones' from a celebrity listing without specifying which is making a category error, not a dose error.
- No doses, no monitoring cadence, no durationhigh
Six compounds are listed with zero dosing information. For peptides this is the standard 'celebrity stack' framing; for hormones it crosses into actively misleading. A reader has no way to evaluate whether Renner's protocol is conservative, supratherapeutic, or being managed by a clinician.
- Celebrity-stack social proof is the active mechanismmedium
@PeptideList's tweet itself flags this — 'celebrity stack gets attention, biology decides if it makes sense.' The list functions as marketing for the peptide market regardless of whether Renner's specific use is sound. Readers should disentangle 'this celebrity uses this' from 'this is therapeutically warranted for me.'
- Compounded research-peptide sourcing for non-FDA-approved compoundsmedium
BPC-157, TB-500, MOTS-c, and (depending on context) Thymosin Alpha-1 are sourced through compounding pharmacies or research-chemical vendors in the US. Independent third-party testing has documented endotoxin contamination, mislabeled doses, and incorrect peptide sequences across this market. Celebrity access to clinic-grade sourcing isn't transferable to retail buyers.
- 'NAD' obscures very different productslow
IV NAD+ ($300–1500 per drip) and oral NMN/NR precursors ($30–80/mo) are listed as the same thing in popular discourse but have wildly different cost structures and evidence profiles. A reader reproducing 'NAD' without specifying which is making an intervention choice they probably don't realize they're making.
'Hormones' covers TRT, GH, IGF-1, thyroid, DHEA, and AAS-territory compounds with wildly different evidence bases and risk profiles. The single most clarifying edit to this listing is to specify which hormones, at what doses. A reader copying 'Hormones' from a celebrity stack without specifying which is making a category error, not a dose error — and that's the difference between a defensible TRT protocol and a self-administered GH stack with no monitoring.
Estimated cost
Wide range because 'NAD' could be $80/mo NMN or $1,200/mo IV NAD; 'Hormones' could be $40/mo generic TRT or $1,500/mo physician-supervised GH stack. Without specifics, this is closer to 'celebrity stack price range' than a real estimate. Compounded peptides (BPC-157, TB-500, MOTS-c, Thymosin) typically run $200–500/mo combined.